OPEN ACCESS pISSN 2234-3806
eISSN 2234-3814

Table. 2.

Table. 2.

Biomarkers concentrations for outcomes

Biomarker* All patients (N=1,760) Occurrence of AKI Status at 28 days Status at 1 yr
No AKI (N=1,031) AKI (N=728) P Survivor (N=1,398) Non-survivor (N=356) P Survivor (N=502) Non-survivor (N=107) P
uNGAL, ng/mL 147.6 (39.9–827.7) 62.6 (27.6–205.4) 697.8 (173.1–1,500) <0.001 111.6 (34.0–581.5) 505.8 (103.5–1,500) <0.001 39.8 (20.4–128.6) 96.1 (35.2–254.6) <0.001
uLFABP, ng/mL 32.4 (10.5–96.0) 19.6 (7.4–60.1) 61.8 (22.6–207.1) <0.001 28.1 (9.2–83.9) 61.3 (18.7–183.3) <0.001 9.2 (3.5–25.8) 11.8 (5.3–45.7) 0.030
uCysC, mg/L 0.33 (0.12–2.05) 0.20 (0.10–1.03) 0.78 (0.19–3.39) <0.001 0.30 (0.12–1.84) 0.52 (0.13–2.76) 0.002 0.11 (0.06–0.23) 0.14 (0.08–0.46) 0.029
pNGAL, ng/mL 197.0 (94.0–464.5) 125.0 (72.0–224.5) 451.0 (233.0–839.0) <0.001 170.0 (85.0–394.0) 380.0 (176.0–799.3) <0.001 106.0 (68.0–172.3) 180.0 (100.0–317.0) <0.001
pCysC, mg/L 1.28 (0.86–2.02) 1.02 (0.75–1.35) 2.02 (1.41–2.88) <0.001 1.19 (0.82–1.80) 1.80 (1.21–2.70) <0.001 1.22 (0.91–1.84) 1.25 (0.90–1.90) 0.880

Values are expressed as median (interquartile range). Group comparisons were performed using the Kruskal–Wallis test. A two-sided P<0.05 was considered for significance.

*Biomarker concentrations for the columns “all patients,” “occurrence of AKI,” and “status at 28 days” were collected on admission and those for the column “status at 1 yr” were collected at discharge from the intensive care unit.

Abbreviations: AKI, acute kidney injury; uNGAL, urinary neutrophil gelatinase-associated lipocalin; uLFABP, urinary liver fatty acid-binding protein; uCysC, urinary cystatin C; pNGAL, plasma neutrophil gelatinase-associated lipocalin; pCysC, plasma cystatin C; AKI, acute kidney injury.

Ann Lab Med 2024;44:144~154 https://doi.org/10.3343/alm.2023.0083

© Ann Lab Med